2Seventy Bio

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

2Seventy Bio reports solid Q2 revenue, navigates competitive challenges

2Seventy Bio's Q2 2023 performance reflects strong revenue driven by ABECMA, with a focus on innovation and patient care. The company faces challenges from competitive dynamics and FDA clinical holds but is strategically positioned to capitalize on opportunities in the oncology space.

2Seventy Bio addresses challenges, highlights ABECMA support at Q3 call

2Seventy Bio navigated a challenging quarter with a focus on ABECMA support and organizational reshaping.
Key presentations at ASH showcased positive outcomes for ABECMA, while concerns around growth and profitability were addressed.
Management's commitment to stakeholders and strategic partnerships position the company for future growth and success.

2Seventy Bio reports robust Q4 earnings, eyes growth opportunities

2Seventy Bio's Q4 2023 earnings call highlighted strong financial performance, cost-saving initiatives, and confidence in Abecma's market potential.
While facing competition challenges and operational considerations, the company remains focused on growth, innovation, and financial sustainability.
Strategic partnerships, upcoming regulatory milestones, and a clear roadmap to breakeven underscore 2Seventy Bio's commitment to long-term success.

2Seventy Bio focuses on Abecma growth post realignment

2Seventy Bio's Q1 2024 performance was solid, with Abecma revenues meeting expectations.
The company's strategic realignment towards Abecma aims for cost efficiency and growth.
Challenges lie in achieving breakeven by 2025 and sustaining Abecma's market position.
Opportunities exist for increased profitability, market expansion, and operational efficiency.

2Seventy Bio focuses on ABECMA, reports strong Q2 earnings

2Seventy Bio's Q2 performance reflects a strategic shift towards profitability and sustainable growth.
The company's strong financial results and cost-saving measures position it well for future success.
While challenges exist, opportunities in product focus and financial management pave the way for a promising future.
Overall, 2Seventy Bio's focus on ABECMA and profitability sets a positive trajectory for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m. ET in New York. A live webcast of the fireside chat will be available via the Investors and Media section of the company's website at https://ir.2seventybio.com. Replays will be archived on the 2seventy bio website for 30 days followi.

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

2seventy bio, Inc. (NASDAQ:TSVT ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs William Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmannn - Chief Medical Officer Conference Call Participants Daina Graybosch - Leerink Kelsey Goodwin - Guggenheim Securities Operator Good day, and thank you for standing by. Welcome to the 2Seventy Bio Second Quarter 2024 Earnings Conference Call.

2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript

2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.83 per share a year ago.

2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the second quarter ended June 30, 2024. “This year has been transformative for 2seventy, and we enter the second half in a strong financial and operational position, poised for commercial growth,” said Chip Baird, CEO. “We dramatically reduced our cost structure and strengthened our balance sheet with the completion of the sale of our oncology R&D business to Rege.

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

Investors need to pay close attention to 2seventy bio (TSVT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?

2seventy bio, Inc. (TSVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join t.

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024

2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma. TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk. Abecma shows favorable clinical data but faces strong competition from Carvykti.

2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition

Paramount Global

Pure Storage

No matter your investing style, we all hope to find overlooked stock gems. These are where the biggest gains are made.

3 Hidden Stock Gems That Wall Street Is Overlooking

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease. The 2seventy bio team currently involved in the program will join No.

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat on Tuesday, May 28, 2024 at 8:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL, on Monday, June 10, 2024 at 8:40 a.m. ET Live webcasts of the fireside chats will be available via.

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs Chip Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmann - Chief Medical Officer Conference Call Participants Rabib Chaudhury - Leerink Partners Matt Leskowitz - Goldman Sachs Kelsey Goodwin - Guggenheim Securities Morgan Gryga - Morgan Stanley John Newman - Canaccord Genuity Operator Good day and thank you for standing by. Welcome to the 2seventy bio First Quarter 2024 Earnings Conference Call.

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.08 per share a year ago.

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024. “In the first quarter of 2024, we have successfully completed a strategic re-alignment to focus exclusively on Abecma, seeking to impact many more patients in earlier lines and return to commercial growth. In turn, we are focused on reaching financial sustainability and creating value for shareholders,” said Chip Baird, CEO, 2se.

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the c.

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

2seventy bio is focusing on ABECMA, their CAR-T cell therapy for multiple myeloma, and expects label expansion approval. ABECMA has shown positive real-world evidence and has the potential for significant market growth. The company's financial position is strong, with a cash runway past 2027, and they anticipate a return to growth if the label expansion is approved.

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business. Going forward, 2seventy bio will focus exclusively on the commercialization and development o.

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the “Board”), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. “We are pleased to welcome Eli and Charlie to the 2seventy Bo.

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

2Seventy Bio, Inc. (NASDAQ:TSVT ) Q4 2023 Earnings Conference Call March 5, 2024 8:00 AM ET Company Participants Elizabeth Hickin - Head, IR Chip Baird - Incoming CEO Vicki Eatwell - Incoming CFO Anna Truppel-Hartmann - SVP, Clinical Development Conference Call Participants Daina Graybosch - Leerink Partners Tommie Reerink - Goldman Sachs & Co. Kelsey Goodwin - Guggenheim Securities Samantha Semenkow - Citigroup Operator Good day, and thank you for standing by. Welcome to the 2seventy bio fourth-quarter 2023 earnings conference call.

2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2023. “In the past weeks and months, 2seventy has made significant changes to our business and cost structure designed to optimize our ability to unlock value for Abecma,” said Chip Baird, incoming CEO. “While Abecma experienced continued competitive headwinds in the fo.

2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress

2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy 2seventy bio (TSVT) Ahead of Earnings?

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2024 at 2:10 p.m. ET Leerink Partners Global Biopharma Conference in Miami, FL on Wednesda.

2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences

2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for 2Seventy Bio Stock (TSVT)